Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Both cases were managed effectively with increased supplementation of calcium carbonate (1,200 mg/day) and calcitriol (0.5 µg/day) prior to the second denosumab administration.
Source: Denosumab-relevant adverse events. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Open-label reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This was a single-center, open-label, single-arm study designed to evaluate the effects of denosumab treatment in pediatric FD/MAS patients.
Source: Methods.
Patients aged 18 years or younger were recruited from the Department of Endocrinology at Peking Union Medical College Hospital (PUMCH).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Denosumab in pediatric patients with fibrous dysplasia/McCune-Albright syndrome: a single-center, open-labeled study
Study design awaiting verification · Frontiers in Endocrinology · 2026
Original publication title
Denosumab in pediatric patients with fibrous dysplasia/McCune-Albright syndrome: a single-center, open-labeled study
Copyright © 2026 Ouyang, Jiajue, Zhou, Qi, Li, Cui, Chi, Pang, Gong, Liu, Jiang, Wang, Li, Xing and Xia.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Investigate the efficacy and safety of denosumab in pediatric FD/MAS population.
Source: ObjectiveAbstract: Context
Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS) is a rare skeletal disorder frequently manifesting in childhood, often leading to progressive bone lesions, pain and functional impairment. Denosumab as a monoclonal antibody targeting RANKL has emerged as a potential therapeutic option, while its safety and efficacy in pediatric population remains poorly defined.
Source: ContextAbstract: Design
12-month single-arm study.
Source: DesignAbstract: Setting
Single center study at Peking Union Medical College Hospital.
Source: SettingAbstract: Patients
FD/MAS patients under 18.
Source: PatientsAbstract: Interventions
Denosumab 1mg/kg with a maximum dosage of 60mg every 3 months for 12-month follow-up.
Source: InterventionsAbstract: Main outcome measures
FD-related bone pain, bone turnover markers, 99mTc-MDP bone scintigraphy, bone mineral density.
Source: Main outcome measuresAbstract: Results
In 5 pediatric FD/MAS patients treated with denosumab, significant clinical improvements were observed, including alleviation of FD-associated bone pain, reductions in bone turnover markers, and regression of FD lesions. Alkaline phosphatase levels dropped to an average of 41.8% of baseline, accompanied by concurrent reductions in C-terminal telopeptide and type 1 N-terminal pro-peptide levels. Adverse events particularly hypercalcemia following treatment cessation occurred in 2 of the 5 patients, indicating a relatively high incidence of rebound hypercalcemia and highlighting the need for careful monitoring and cautious use of denosumab in pediatric patients.
Source: ResultsAbstract: Conclusions
Denosumab appears to be effective in pediatric FD/MAS patients, however safety concerns remain. Comprehensive pre-treatment evaluation and close monitoring throughout the treatment course are essential. Further prospective studies and randomized controlled trials are needed to determine optimal dosing strategies and establish long-term safety in this population.
Source: ConclusionsAuthors’ abstract
Context
Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS) is a rare skeletal disorder frequently manifesting in childhood, often leading to progressive bone lesions, pain and functional impairment. Denosumab as a monoclonal antibody targeting RANKL has emerged as a potential therapeutic option, while its safety and efficacy in pediatric population remains poorly defined.
Objective
Investigate the efficacy and safety of denosumab in pediatric FD/MAS population.
Design
12-month single-arm study.
Setting
Single center study at Peking Union Medical College Hospital.
Patients
FD/MAS patients under 18.
Interventions
Denosumab 1mg/kg with a maximum dosage of 60mg every 3 months for 12-month follow-up.
Main outcome measures
FD-related bone pain, bone turnover markers, 99mTc-MDP bone scintigraphy, bone mineral density.
Results
In 5 pediatric FD/MAS patients treated with denosumab, significant clinical improvements were observed, including alleviation of FD-associated bone pain, reductions in bone turnover markers, and regression of FD lesions. Alkaline phosphatase levels dropped to an average of 41.8% of baseline, accompanied by concurrent reductions in C-terminal telopeptide and type 1 N-terminal pro-peptide levels. Adverse events particularly hypercalcemia following treatment cessation occurred in 2 of the 5 patients, indicating a relatively high incidence of rebound hypercalcemia and highlighting the need for careful monitoring and cautious use of denosumab in pediatric patients.
Conclusions
Denosumab appears to be effective in pediatric FD/MAS patients, however safety concerns remain. Comprehensive pre-treatment evaluation and close monitoring throughout the treatment course are essential. Further prospective studies and randomized controlled trials are needed to determine optimal dosing strategies and establish long-term safety in this population.
Publication and source details
Original title: Denosumab in pediatric patients with fibrous dysplasia/McCune-Albright syndrome: a single-center, open-labeled study
Quanshi Ouyang; Ruizhi Jiajue; Ruotong Zhou; Wenting Qi; Xiang Li; Lijia Cui; Yue Chi; Qianqian Pang; Yiyi Gong; Wei Liu; Yan Jiang; Ou Wang; Mei Li; Xiaoping Xing; Weibo Xia
Frontiers in Endocrinology · 2026
* Correspondence: Weibo Xia, xiaweibo8301@163.com†These authors share first authorship
‡ORCID: Weibo Xia, orcid.org/0000-0001-7768-5536
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T00:00:18.431858+00:00
DOI: 10.3389/fendo.2026.1762370 · PMC12956703